Li-wei Wang

发表

[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].

Jianming Xu, L. Shen, M. Tao, 2013, Zhonghua zhong liu za zhi [Chinese journal of oncology].

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.

Ying Cheng, Y. Ba, Jianming Xu, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.

Ying Cheng, Jianming Xu, M. Tao, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology

Yangqiu Li, Yingyong Hou, Ying Cheng, 2019, Cancer biology & medicine.

Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

Jianming Xu, Yunpeng Liu, L. Shen, 2014, Gastric Cancer.

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.

Ying Cheng, Tae Won Kim, T. Yau, 2015, The Lancet. Oncology.

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial

Y. Ba, Jianming Xu, Jun Liang, 2011, Chinese journal of cancer.

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

Ying Cheng, L. Shen, F. Bi, 2016, BMC Cancer.

Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study

Jianming Xu, L. Shen, R. Xu, 2017, Journal of Hematology & Oncology.

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Ying Cheng, Jianming Xu, Yunpeng Liu, 2019, Cancer communications.

Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

N. Xu, Ying Cheng, P. Lagiou, 2017, Journal of Hematology & Oncology.

First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.

Ying Cheng, L. Shen, S. Qin, 2021 .

A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.

Ying Cheng, L. Shen, F. Bi, 2014 .

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial

Ying Cheng, Jianming Xu, Wei Li, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.

S. de Vos, H. Holte, S. Leppä, 2022, Journal of Clinical Oncology.

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

R. Xu, H. Pan, Yanqiao Zhang, 2017, BMC Cancer.

Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial

Ying Cheng, T. Yau, Y. Ba, 2020, Journal of gastroenterology and hepatology.

Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study.

Ying Cheng, Bing-he Xu, Z. Guan, 2012, Chinese Medical Journal.

O-0023CONCUR: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF REGORAFENIB MONOTHERAPY IN ASIAN PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (MCRC)

Jianming Xu, R. Xu, H. Pan, 2014 .

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

Jianming Xu, L. Shen, R. Xu, 2017, BMC Cancer.

Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.

T. Phillips, P. Lugtenburg, J. Brody, 2022, Journal of Clinical Oncology.

First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.

J. Brody, F. Offner, S. Snauwaert, 2022, Journal of Clinical Oncology.

Subcutaneous epcoritamab + R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): Preliminary phase 1/2 results.

S. de Vos, P. Abrisqueta, T. Phillips, 2022, Journal of Clinical Oncology.

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.

Y. Ba, Shiying Yu, Z. Guan, 2011, Chinese journal of cancer.